This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Yoshimoto Yusuke0 个研究点目标入组 80 人开始时间: 2023年5月15日最近更新: 2023年10月17日

适应症

试验速览

阶段: 2 期
状态: 招募中
发起方
入组人数: 80

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 18age old 至 ot applicable（—）
性别: All

入选标准

•Body weight > 35 kg.
•- Previously untreated for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (excluding undifferentiated carcinoma per the histological classification of gastric tumours in the fifth edition of the WHO classification of 2019).
•- Prior neo-adjuvant and/or adjuvant chemotherapy, radiotherapy and/or chemoradiotherapy for gastric cancer or GEJ cancer are acceptable, but the last administration of the prior regimen (whichever was given last) must have been completed at least 6 months prior to the diagnosis of unresectable or metastatic disease. Diagnosis of unresectable or metastatic disease must be within the 3 months before treatment allocation. Palliative radiotherapy is allowed and must be completed 2 weeks prior to treatment allocation.
•- Willing and able to provide an adequate tumour sample (fresh or archived) for biomarker analyses.
•- Has measurable target disease assessed by the Investigator based on RECIST 1.1. Tumour lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
•- Has an EOCG performance status of 0 to 1.
•- Must have a life expectancy of at least 12 weeks.
•- Has adequate organ and bone marrow function within 14 days before treatment allocation

排除标准

•- Participants with HER2-positive (3+ by IHC, or 2+ by IHC and positive by ISH] or indeterminate gastric or GEJ carcinoma.
•- Untreated or progressive CNS metastatic disease, any leptomeningeal disease, or cord compression. Note: Participants previously treated for CNS metastases who are asymptomatic, clinically stable, and who do not require corticosteroids (at doses > 10 mg of prednisone or equivalent) for at least 14 days prior to the first dose of study intervention are not excluded.
•- Participants with ascites which cannot be controlled with appropriate interventions.
•- Active infectious disease(s):
•(a) Active infection including TB (clinical evaluation that includes clinical history, physical examination, and radiographic findings and TB testing in line with local practice).
•(b) Human immunodeficiency virus infection. Participants should be tested for HIV prior to treatment allocation if required by local regulations or IRB/IEC.
•(c) Chronic or active or uncontrolled hepatitis B. Refer to Section 8.2.4.
•(d) Chronic or active or uncontrolled hepatitis C, defined as anti-HCV IgM/IgG positive and HCV-RNA detectable by PCR.
•(e) Active hepatitis A: HAV-IgM positive.
•- Uncontrolled intercurrent illness.
•- Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
•- Known DPD enzyme deficiency based on local laboratory testing where testing is SoC.
•- Known allergy or hypersensitivity to BSP agents or any of the excipients of the BSP agents.
•- Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment.
•- Any prohibited medication listed in Protocol. Current or prior use of immunosuppressive medication within 14 days before the first dose of study intervention should be excluded, The following are exceptions to this criterion:
•(a) Intranasal, inhaled, topical steroids, or local steroid injections (eg, intraarticular injection).
•(b) Systemic corticosteroids at physiological doses not to exceed 10 mg/day of prednisone or equivalent.
•(c) Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication).
•(d) A single dose for palliative purpose (eg, pain control).
•- Major surgery within 4 weeks prior to the first dose of study intervention or still recovering from prior surgery. Note: Local surgery of isolated lesions for palliative intent is acceptable.
•- Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks of the first dose of study intervention.

研究者

发起方

Yoshimoto Yusuke

相似试验

招募中

1 期

Master Protocol of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer

CTIS2022-502317-29-00AstraZeneca AB260

进行中（未招募）

1 期

A phase II, open-label, multicentre, pharmacokinetic, pharmacodynamic and safety study of anagrelide hydrochloride in young (18-50 years) and elderly (= 65 years) patients with essential thrombocythaemia.Xagrid is an antineoplasic indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.

EUCTR2004-004058-20-ESShire Pharmaceutical Development Limited24

进行中（未招募）

1 期

EUCTR2004-004058-20-GBShire Pharmaceutical Development Limited24

进行中（未招募）

不适用

EUCTR2004-004058-20-SEShire Pharmaceutical Development Limited24

进行中（未招募）

不适用

EUCTR2004-004058-20-DEShire Pharmaceutical Development Limited24